Metabolic Health Articles - Page 49

GLP-1s Reduce Substance Addiction Risk in US Veterans: BMJ Study

An observational study in the British Medical Journal reveals GLP-1 medications like semaglutide significantly lower substance use disorder (SUD) risk in US veterans with type 2 diabetes. Compared to SGLT2 inhibitors, GLP-1s reduced new addiction risks by up to 25% and improved outcomes like 50% fewer substance-related deaths. These findings challenge traditional views on addiction and metabolic health.

Shotlee·Mar 10, 2026·5 min read

GLP-1 Medications

The Himsification of Medicine: Super Bowl Ad & Semaglutide Clash

Hims & Hers made waves with a Super Bowl ad promoting preventive care through tailored prescriptions and peptides for everyday Americans. But announcing compounded oral semaglutide triggered an FDA investigation and a swift lawsuit from Novo Nordisk. The quick settlement highlights battles over GLP-1 access and drug pricing.

Shotlee·Mar 10, 2026·4 min read

GLP-1 Medications

Lindt: GLP-1 Users Eating More Chocolate, Not Less

Contrary to predictions, chocolate sales are surging among GLP-1 weight-loss drug users in the U.S., according to Swiss chocolatier Lindt & Spruengli. An internal analysis reveals these households account for 17.5% of chocolate purchases, with premium varieties rising nearly 17%. This challenges assumptions about appetite suppression from drugs like Ozempic and Mounjaro.

Shotlee·Mar 10, 2026·5 min read

GLP-1 Medications

Healthier Happy Selects CoreAge Rx as Top Tirzepatide Online Destination

Independent health platform Healthier Happy has chosen CoreAge Rx as its preferred destination for tirzepatide online, highlighting its physician-supervised telehealth model, straightforward pricing, and direct-to-home delivery. This recognition underscores CoreAge Rx's role in simplifying access to GLP-1 therapies like tirzepatide and semaglutide for metabolic health.

Shotlee·Mar 10, 2026·5 min read

Weight Loss Supplements

Burn Slim Exposed: Real Users Reveal GLP-1 Mimetic Effects

Burn Slim Capsules are gaining attention as a natural GLP-1 mimetic alternative to prescription drugs like semaglutide. Real users report dramatic appetite changes, consistent fat loss up to 22 pounds in 12 weeks, and sustained results without muscle loss or loose skin. Backed by studies on its four key ingredients, this guide exposes the science and user truths.

Shotlee·Mar 9, 2026·6 min read

Diagnostics & Monitoring

Babson Fingertip Blood Tests Now Include GLP-1 Monitoring

Babson Diagnostics, crowned Medtech Company of the Year in 2024, now offers GLP-1 monitoring through its innovative fingertip blood tests. Patients on GLP-1 medications like Wegovy can pick up prescriptions and get comprehensive bloodwork in one pharmacy stop. This pea-sized sample panel tracks key metrics for safer, more effective therapy.

Shotlee·Mar 9, 2026·7 min read

GLP-1 Medications

Amazon Pharmacy Adds Zepbound KwikPen to Same-Day Delivery

Amazon Pharmacy is streamlining GLP-1 access by adding Zepbound KwikPen to its same-day delivery service. This multi-dose device holds a full month's supply, addressing manufacturing bottlenecks and offering $299 cash-pay pricing—far below traditional $1,000 quotes. Integrated with Amazon One Medical, it provides personalized care for weight management and obstructive sleep apnea patients.

Shotlee·Mar 9, 2026·4 min read

GLP-1 Medications

Aspen Plans Mounjaro Rollout in Sub-Saharan Africa

South Africa's Aspen Pharmacare is accelerating Mounjaro's rollout across sub-Saharan Africa after its explosive success at home, where the GLP-1 market tripled to $133.6 million. With over half the market share and $78.97 million in projected sales, this expansion tests rapid access to advanced weight-loss therapies. Here's how Aspen's KwikPen approval paves the way.

Shotlee·Mar 9, 2026·4 min read

GLP-1 Medications

Hims & Hers, Novo Nordisk End Lawsuit, Collaborate on Wegovy Sales

In a surprise turn, Novo Nordisk is dropping its lawsuit against Hims & Hers Health, paving the way for branded Wegovy and Ozempic sales on the telehealth platform. This follows Hims' brief plan for cheaper compounded versions and FDA warnings on shortages. Patients gain better access to approved GLP-1 medications.

Shotlee·Mar 9, 2026·5 min read

Metabolic Health

Latest Articles

GLP-1s Reduce Substance Addiction Risk in US Veterans: BMJ Study

The Himsification of Medicine: Super Bowl Ad & Semaglutide Clash

Lindt: GLP-1 Users Eating More Chocolate, Not Less

Healthier Happy Selects CoreAge Rx as Top Tirzepatide Online Destination

Burn Slim Exposed: Real Users Reveal GLP-1 Mimetic Effects

Babson Fingertip Blood Tests Now Include GLP-1 Monitoring

Amazon Pharmacy Adds Zepbound KwikPen to Same-Day Delivery

Aspen Plans Mounjaro Rollout in Sub-Saharan Africa

Hims & Hers, Novo Nordisk End Lawsuit, Collaborate on Wegovy Sales

People Taking GLP-1 Weight Loss Drugs Like Ozempic and Wegovy Started Moving Less

Ozempic, Mounjaro & More: Yale Study Exposes Risky Online GLP-1 Prescribing

GLP-1 Drugs Linked to Skin Pain: New Reports of Dysesthesia & Allodynia

Beyond Healthspan: The New Midlife Goal for Men

Ozempic and Similar Weight-Loss Medications Linked to 30% Lower Breast Cancer Risk